EP1663144A1 - Preparations a base d'acetonide de triamcinolone et d'acetate d'anecortave pour injection - Google Patents

Preparations a base d'acetonide de triamcinolone et d'acetate d'anecortave pour injection

Info

Publication number
EP1663144A1
EP1663144A1 EP04782985A EP04782985A EP1663144A1 EP 1663144 A1 EP1663144 A1 EP 1663144A1 EP 04782985 A EP04782985 A EP 04782985A EP 04782985 A EP04782985 A EP 04782985A EP 1663144 A1 EP1663144 A1 EP 1663144A1
Authority
EP
European Patent Office
Prior art keywords
suspension composition
injection
eye
anecortave acetate
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04782985A
Other languages
German (de)
English (en)
Inventor
Rajni Jani
Ernesto J. Castillo
Wesley Wehsin Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of EP1663144A1 publication Critical patent/EP1663144A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Definitions

  • the present invention relates to injectable formulations used for treating diseases or conditions of the eye. More particularly, the present invention relates to formulations of the steroid triamcinolone or the cortisene anecortave acetate that are designed for injection into the eye.
  • Injectable compositions containing triamcinolone acetonide have been available for many years.
  • Commercial products include Kenalog ® -10 Injection (triamcinolone acetonide injectable suspension, USP) and Kenalog ® -40 Injection (triamcinolone acetonide injectable suspension, USP), which are marketed by Bristol-Myers Squibb Co. These products contain 10 mg/ml or 40 mg/ml of trimacinoione acetonide, respectively. According to its package insert, Kenalog-40 Injection is approved for certain intramuscular and intra- articular uses.
  • Kenalog-40 Injection is indicated for intramuscular use in certain cases for endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, and edematous state.
  • the specific approved ophthalmic indication is "[sjevere chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus; ulceris; iridocyclitis; chorioretinitis; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; and anterior segment inflammation.
  • Kenalog-40 Injection is indicated for intra-articular or intrabursal administration, and for injection into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute nonspecific tenosynovitis; and posttraumatic osteoarthritis.
  • Kenalog ® -40 Injection to treat diabetic macular edema
  • the product is injected into the vitreous of patients suffering from diabetic macular edema.
  • the product is processed by the physician in an attempt to remove the preservative that is present in the Kenalog-40 Injection formulation supplied by Bristol-Myers Squib Co. because the preservative may be irritating in to the vitreous and tissues in the posterior segment of the eye.
  • the commercially available product must be used immediately after it is shaken to avoid settling; the package insert reads as follows: "After withdrawal [from the shaken product vial], inject without delay to prevent settling in the syringe.”
  • Anecortave acetate is a compound known to be useful for treating ocular angiogenesis-related disorders.
  • U.S. Patent No. 6,011 ,023 discloses certain compounds, including anecortave acetate, useful for treating and preventing ocular neovascularization.
  • Various formulations are described in the '023 patent, including formulations for sterile intraocular injection.
  • the present invention provides improved triamcinolone acetonide and anecortave acetate suspension compositions that are particularly suited for injection into the eye.
  • the improved suspension compositions have excellent settling characteristics, are easily resuspended with gentle-shaking, are preservative-free and surfactant-free, and are capable of being smoothly and easily injected through 30-gauge needles.
  • the present invention is based on the finding that a suspension composition of triamcinolone acetonide or anecortave acetate that has improved settling characteristics relative to the currently available Kenalog-40 Injection triamcinolone acetonide composition can be obtained without the need to include any surfactant ingredient.
  • the present invention is also based on the finding that such a trimacinoione acetonide or anecortave acetate suspension composition that lacks a surfactant ingredient can also be more easily injected through a 30-ga. cannula than the currently available Kenalog-40 Injection triamcinolone acetonide composition.
  • the suspension compositions of the present invention consist essentially of trimacinoione acetonide or anecortave acetate, polyvinylpyrrolidone, a tonicity-adjusting agent, a buffering agent and water for injection.
  • Triamcinolone acetonide is a steroid that can be made by known methods and is commercially available even in micronized forms. It is important that the triamcinolone acetonide be sized so that mean volume diameter is 4 ⁇ m or less, preferably 3 ⁇ m or less, with a standard deviation of around 2 ⁇ m or less. Sizing techniques, such as ball-milling, are known and can be used to attain these particle size and distribution requirements.
  • the suspension compositions of the present invention contain from 0.1 - 25 % of trimacinoione acetonide, and, if designed for injection into the posterior segment of the eye, are preferably formulated so that they contain 4 %, 8 %, 16 %, or 25% of trimacinoione acetonide. Most preferred are suspension compositions containing 4 % or 8% of trimacinoione acetonide.
  • Anecortave acetate is a known angiostatic cortisene compound. As in the case of triamcinolone acetonide, it is important that the anecortave acetate be sized so that mean volume diameter is 4 ⁇ m or less, preferably 3 ⁇ m or less, with a standard deviation of around 2 ⁇ m or less. Sizing techniques, such as ball-milling, are known and can be used to attain these particle size and distribution requirements.
  • the suspension compositions of the present invention generally contain from 1 - 16 % of anecortave acetate.
  • the concentration of anecortave acetate is preferably from 3 - 6 %, and most preferably 3 %. If the suspension is designed to be injected into the vitreous, the concentration of anecortave acetate is preferably such that the injection delivers from 4 - 50 mg of anecortave acetate.
  • the suspension compositions of the present invention contain polyvinylpyrrolidone in an amount sufficient to enhance the physical stability of the suspension composition and disperse and wet the drug during any drug sizing process.
  • the polyvinylpyrrolidone ingredient included in the compositions of the present invention has a weight average molecular weight of about 5000 - 1 ,600,000. Most preferred is polyvinylpyrrolidone having a weight average molecular weight of about 55,000 — 60,000.
  • the amount of polyvinylpyrrolidone that should be used in the suspension compositions of the present invention varies with the concentration of trimacinoione acetonide or anecortave acetate, but in general will be from 0.5 - 8 %.
  • a suitable amount of polyvinylpyrrolidone is 0.5 - 1.5 %, preferably 1.0 %.
  • a suitable amount of polyvinylpyrrolidone is 1.5 - 3 %, preferably 2 %.
  • a suitable amount of polyvinylpyrrolidone is 3 - 8 %, preferably 4 - 6 %.
  • a suitable concentration of polyvinylpyrrolidone is 0.5 - 1.5 %, preferably 1.0 %.
  • T e compositions of the present invention have a viscosity of 50 cps. or less, preferably 15 cps. or less, and most preferably 10 cps. or less. They settle very slowly and resuspend readily. This relatively low viscosity ensures that the product is easily processed during manufacturing, transfer and filling operations, and is easily extruded through 27-gauge or 30-gauge needles.
  • the compositions of the present invention contain a tonicity-adjusting agent, such as sodium chloride or mannitol.
  • a tonicity-adjusting agent such as sodium chloride or mannitol.
  • the tonicity-adjusting agent is sodium chloride.
  • the tonicity- adjusting agent is present in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150 - 450 mOsm).
  • the final composition has an osmolality of 250 - 350 mOsm, and most preferably, the suspension composition of the present invention has an osmolality of 270 - 320 mOsm.
  • the suspension compositions of the present invention also contain a pH-adjusting agent to adjust the pH of the compositions to pH 6 - 8.
  • the suspension compositions contain a buffering agent to maintain the pH of the compositions within the range of pH 6 - 8, preferably pH 7.0 - 7.6.
  • Suitable buffering agents include phosphate buffering agents such as monobasic sodium phosphate (dihydrate) and dibasic sodium phosphate (dodecahydrate).
  • the suspension compositions of the present invention are preferably packaged in unit dose containers, such as glass or plastic vials.
  • the suspension compositions can also be packaged in pre-filled syringes or cartridges.
  • the suspension compositions are preferably packaged in glass vials.
  • injection “into the posterior segment of the eye” includes, but is not limited to, injection into the vitreous body, injection into or beneath the sclera, and injection external to the vitreous and beneath the Tenon's capsule.
  • the present invention relates to a method of treating macular edema including but not limited to diabetic macular edema, or retinal vein occlusion, including central and branch retinal vein occlusions, comprising injecting into the posterior segment of the eye a suspension composition that is preservative-free and surfactant-free and that consists essentially of trimacinoione acetonide, polyvinylpyrrolidone, an ionic tonicity- adjusting agent, a buffering agent and water for injection.
  • a suspension composition that is preservative-free and surfactant-free and that consists essentially of trimacinoione acetonide, polyvinylpyrrolidone, an ionic tonicity- adjusting agent, a buffering agent and water for injection.
  • the present invention relates to a method of treating post-surgical inflammation comprising injecting into the anterior segment of the eye a suspension composition that is preservative-free and surfactant-free and that consists essentially of trimacinoione acetonide, polyvinylpyrrolidone, an ionic tonicity-adjusting agent, a buffering agent and water for injection.
  • the present invention relates to a method of treating an ophthalmic disease or condition in the posterior segment of the eye, including but not limited to macular degeneration, comprising injecting into the posterior segment of the eye a suspension composition that is preservative-free and surfactant-free and that consists essentially of anecortave acetate, polyvinylpyrrolidone, an ionic tonicity-adjusting agent, a buffering agent and water for injection.
  • Example 4 Settling Study The compositions of Examples 1 - 3 and Comparative Example 1 were evaluated to determine their settling characteristics. After preparing the compositions, each was transferred to a graduated cylinder and stored at room temperature. Visual observations were made at the time points indicated in Table 3 below and the sedimentation volume ratio (%) was recorded. Sedimentation volume ratio (%) was calculated as follows: (sedimentation volume/total volume) x 100.
  • compositions of Examples 1 - 3 and Comparative Example 1 were evaluated to determine their 'syringeability' - the relative ease with which they could be extruded through a needle of a given size.
  • the compositions of Examples 1 - 3 and Comparative Example 1 were tested using an Instron machine (Model 4501 ; Load Cell Model 2525-807, capacity 22.48 lbs., used for all samples except Comp. Ex. 1 ; Load Cell Model 2518-805, capacity 1124 lbs., used for Comp. Ex. 1 samples) to determine the amount of force (pound foot) required to extrude them from syringes using two needle sizes: 27-ga. and 30-ga.
  • Viscosity, average particle size, and resuspendability were determined for the compositions of Examples 1 - 3 and Comparative Example 1. Viscosity was determined using a Brookfield viscometer (CP-42 at 30 RPM). Resdispersibility was determined by visual inspection of hand-shaken samples. The results are shown in Table 5. TABLE 5 Ex. 1 - 3 Comp. Ex. 1
  • Viscosity (cps) 2 (Ex. 1 : 40 mg/mL) 18 7 (Ex. 3: 160 mg/mL)
  • compositions of Examples 7 and 8 were evaluated to determine their settling characteristics. After preparing the compositions, each was transferred to a graduated cylinder and stored at room temperature. Visual observations were made at the time points indicated in Table 7 below and the sedimentation volume ratio (%) was recorded. Sedimentation volume ratio (%) was calculated as follows: (sedimentation volume/total volume) x 100.
  • compositions of Examples 7 and 8 were evaluated to determine their 'syringeability' - the relative ease with which they could be extruded through a needle of a given size.
  • the compositions were tested using an Instron machine (Model 4501 ; Load Cell Model 2525-807, capacity 22.48 lbs., used for all samples) to determine the amount of force (pound foot) required to extrude them from syringes using two needle sizes: 27-ga. and 30-ga.
  • the rate of expression was kept constant at either of two (calculated) speeds: fast (Instron head 8.8 mL/min. or 20 in./min) or slow (Instron head 0.85 mL/min. or 1.93 in./min.).
  • the samples were loaded into a tuberculin syringe by withdrawing them through an 18-ga. needle. After filling the syringe to approximately the 1cc level, the 18-ga. needle was removed and either the 30-ga. or 27-ga. needle was attached. The syringe was then placed in the Instron machine and the extrusion force was measured. Ten determinations were made for each sample at each needle size and at each speed and an average value was determined (except as noted). The data is presented in Table 8 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions injectables d'acétonide de triamcinolone ou d'acétate d'anécortave. Ces compositions conviennent particulièrement à une injection dans le segment postérieur de l'oeil en vue du traitement de maladies ophtalmiques.
EP04782985A 2003-09-23 2004-09-02 Preparations a base d'acetonide de triamcinolone et d'acetate d'anecortave pour injection Withdrawn EP1663144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50538603P 2003-09-23 2003-09-23
PCT/US2004/028598 WO2005032510A1 (fr) 2003-09-23 2004-09-02 Preparations a base d'acetonide de triamcinolone et d'acetate d'anecortave pour injection

Publications (1)

Publication Number Publication Date
EP1663144A1 true EP1663144A1 (fr) 2006-06-07

Family

ID=34421523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04782985A Withdrawn EP1663144A1 (fr) 2003-09-23 2004-09-02 Preparations a base d'acetonide de triamcinolone et d'acetate d'anecortave pour injection

Country Status (13)

Country Link
US (1) US20050065137A1 (fr)
EP (1) EP1663144A1 (fr)
JP (1) JP2007506678A (fr)
KR (1) KR20060095974A (fr)
CN (1) CN1852700A (fr)
AR (1) AR045943A1 (fr)
AU (1) AU2004277864A1 (fr)
BR (1) BRPI0414699A (fr)
CA (1) CA2539023A1 (fr)
MX (1) MXPA06003185A (fr)
RU (1) RU2006113593A (fr)
TW (1) TW200518760A (fr)
WO (1) WO2005032510A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
ITRM20050547A1 (it) * 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
CA2717605C (fr) * 2008-03-11 2012-05-15 Alcon Research Ltd. Suspensions d'acetonide de triamcinolone tres floculees et de faible viscosite pour injection intravitreenne
TWI580441B (zh) 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
CN101893619B (zh) * 2010-02-10 2013-11-13 上海蓝怡科技有限公司 改进乳胶悬浊液稳定性的方法
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
CA3240136A1 (fr) * 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methodes et dispositifs pour le traitement de maladies oculaires chez les sujets humains
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
EP3003454B1 (fr) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Appareil pour une administration de médicament à l'aide de multiples réservoirs
RU2710491C2 (ru) 2014-06-20 2019-12-26 Клиасайд Байомедикал, Инк. Устройство для инъекции лекарственного средства в глазную ткань и способ инъекции лекарственного средства в глазную ткань
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
EP3413851B1 (fr) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Emballage
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
WO2018204515A1 (fr) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Procédés d'administration ciblée de médicament au moyen d'une microaiguille
WO2019136512A1 (fr) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Dispositif médical et composition pharmaceutique pour le traitement d'une maladie ou affection de l'œil

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
US6172054B1 (en) * 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
ES2284202T3 (es) * 1997-05-14 2007-11-01 Senju Pharmaceutical Co., Ltd. Preparaciones acuosas en suspension con excelente redispersabilidad.
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
PL203797B1 (pl) * 1999-04-09 2009-11-30 Ortho Mcneil Pharm Inc Kompozycje farmaceutyczne erytropoetyny
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
JP5000835B2 (ja) * 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
CA2436418A1 (fr) * 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Procede de production de nanoparticules et de microparticules par congelation par pulverisation dans un liquide
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
RU2005129278A (ru) * 2003-02-20 2006-01-27 Алькон, Инк. (Ch) Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз
CN1750828A (zh) * 2003-02-20 2006-03-22 爱尔康公司 类固醇治疗眼病患者的用途
US20040186084A1 (en) * 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005032510A1 *

Also Published As

Publication number Publication date
CN1852700A (zh) 2006-10-25
JP2007506678A (ja) 2007-03-22
BRPI0414699A (pt) 2006-11-28
RU2006113593A (ru) 2006-08-27
MXPA06003185A (es) 2006-06-23
AR045943A1 (es) 2005-11-16
WO2005032510A1 (fr) 2005-04-14
CA2539023A1 (fr) 2005-04-14
KR20060095974A (ko) 2006-09-05
US20050065137A1 (en) 2005-03-24
TW200518760A (en) 2005-06-16
AU2004277864A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
US20050065137A1 (en) Triamcinolone acetonide and anecortave acetate formulations for injection
CA2717605C (fr) Suspensions d'acetonide de triamcinolone tres floculees et de faible viscosite pour injection intravitreenne
US8846094B2 (en) Peripherally administered viscous formulations
EA032183B1 (ru) Устройство для внутриглазной доставки лекарственного средства, способ его получения и способы его применения
JP2016510329A (ja) 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
US7820194B2 (en) Combinations of viscoelastics for use during surgery
EP1455750B1 (fr) Combinaisons de produits viscoelastiques a l'usage de la chirurgie
US20050215516A1 (en) New free-radical scavenger containing viscoelastic composition, methods of use and package
EP4185299A1 (fr) Implant intraoculaire à charge élevée d'un prostamide
RU2336074C2 (ru) Композиции и способы лечения заднего сегмента глаза
HK1146464B (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
ZA200603549B (en) Compositions and methods for treating a posterior segment of an eye
MXPA06005146A (en) Compositions and methods for treating a posterior segment of an eye

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401